Table 1.

Baseline clinical and exercise tolerance test characteristics of randomized patients

	Ivabradine (n = 449)	Placebo (n = 440)	P-value
Age, years	59.6 ± 7.6	60.1 ± 8.0	0.30
Male, n (%)	380 (84.6)	370 (84.1)	0.82
Smoker (including ex-smoker), n (%)	271 (60.4)	250 (56.8)	0.28
CCS angina class, I/II/III, %	21.2/67.0/11.8	17.7/70.2/12.0	0.43
Previous MI, n (%)	225 (50.1)	226 (51.4)	0.71
Previous PCI, n (%)	95 (21.2)	89 (20.2)	0.49
Previous CABG, n (%)	135 (30.1)	123 (28.0)	0.73
Diabetes mellitus, n (%)	97 (21.6)	96 (21.8)	0.94
Concomitant treatments at inclusion
Acetylsalicylic acid, n (%)	369 (82.2)	373 (84.8)	0.30
Statins, n (%)	341 (75.9)	330 (75.0)	0.74
ACE-inhibitors, n (%)	235 (52.3)	252 (57.3)	0.21
Supine BP (mmHg) systolic	127.3 ± 12.0	127.6 ± 12.6	0.67
Supine BP (mmHg) diastolic	78.6 ± 7.4	78.1 ± 7.2	0.27
Heart rate at rest (b.p.m.)
Mean ± SD	66.9 ± 6.9	67.2 ± 6.9	0.57
Min–max	41–99	53–107
Total exercise duration (s)
Mean ± SD	445.1 ± 105.5	451.1 ± 107.4	0.40
Min–max	224–716	221–720
Time to limiting angina (s)
Mean ± SD	441.4 ± 105.6	446.7 ± 107.2	0.46
Min–max	223–716	216–715
Time to angina onset (s)
Mean ± SD	351.3 ± 104.5	357.0 ± 104.5	0.42
Min–max	129–659	81–674
Time to 1 mm ST-segment depression (s)
Mean ± SD	338.1 ± 97.2	347.1 ± 103.4	0.18
Min–max	185–655	185–715
Heart rate at peak exercise (b.p.m.)
Mean ± SD	128.6 ± 16.9	129.9 ± 18.0	0.29
Min–max	82–179	75–179
RPP at rest (b.p.m. × mmHg)
Mean ± SD	9389 ± 1661	9427 ± 1830	0.75
Min–max	5800–15 200	4500–20 320
RPP at peak exercise (b.p.m. × mmHg)
Mean ± SD	21 110 ± 4300	21 249 ± 4566	0.64
Min–max	10 660–36 800	10 500–34 500

Mean values ± standard deviation unless otherwise stated. BP, blood pressure; CABG, coronary artery bypass graft; CCS, Canadian Cardiovascular Society classification; MI, myocardial infarction; PCI, percutaneous coronary intervention; RPP, rate–pressure product.